PBMC

Cytek® Biosciences Introduces New 25-Color Immunoprofiling Assay

Thursday, October 7, 2021 - 3:00pm

Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the launch of a new 25-color immunoprofiling assay .

Key Points: 
  • Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the launch of a new 25-color immunoprofiling assay .
  • Cyteks new immunoprofiling assay is built on Cyteks extensive experience pioneering and revolutionizing full spectrum flow cytometry to offer a more comprehensive understanding of the human immune system.
  • Our new immunoprofiling assay offering underscores our commitment to jumpstart immunology discovery using full spectrum flow cytometry and offering a total solution to our users.
  • Cytek, cFluor, Full Spectrum Profiling, FSP and Northern Lights are trademarks or registered trademarks of Cytek Biosciences, Inc.

CerbACT Asia Holds Ribbon Cutting to Celebrate New Immuno-oncology Centre of Excellence

Thursday, October 7, 2021 - 10:48am

The opening ceremony held on the 30th September 2021, was attended by distinguished guests virtually and in-person, marking the start of operations and expansion of the precision medicine offer in Asia.

Key Points: 
  • The opening ceremony held on the 30th September 2021, was attended by distinguished guests virtually and in-person, marking the start of operations and expansion of the precision medicine offer in Asia.
  • "Everyone here at CerbACT Asia is fully committed to provide high-quality results to our clients and hope to improve patient outcomes through precision medicine," says Dr George Wei, Managing Director of CerbACT Asia.
  • Together, we offer a broader range of top-notch technologies and services in Asia.
  • CerbACT Asia is an Immuno-Oncology Centre of Excellence that empowers precision medicine development and drives better patient outcomes by applying deep biomarker expertise to research and clinical development strategies.

Human Milk Supplement Shown to Boost Immunological Activity

Tuesday, September 14, 2021 - 1:38pm

The study evaluated the impact of Human Milk BionutrientsTM (HMBsTM) treatment in human-derived PBMC's against K562 cells, a commonly used immortalized leukemia cell line.

Key Points: 
  • The study evaluated the impact of Human Milk BionutrientsTM (HMBsTM) treatment in human-derived PBMC's against K562 cells, a commonly used immortalized leukemia cell line.
  • In these experiments, human milk bionutrients were added to PMBC's in the presence of K562 and treated for 48-hours.
  • Trulacta is composed entirely of thousands of beneficial components found in human milk, all of which are essential for health and wellbeing.
  • The company's flagship product Trulactais the world's first supplement for adults entirely composed of Human Milk Bionutrients (HMB's), the rich multitude of beneficial nutrients contained in human milk.